19 September 2025
FDA Approves Merck's Subcutaneous KEYTRUDA QLEX for Solid Tumors
KEYTRUDA QLEX, a subcutaneous immune checkpoint inhibitor, offers comparable efficacy to IV KEYTRUDA in treating metastatic NSCLC, with administration possible in one minute by healthcare providers.